Skip to main content
Erschienen in:

01.12.2014 | Myeloproliferative Disorders (C Harrison, Section Editor)

An Immune Dysregulation in MPN

verfasst von: Giovanni Barosi

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose to MPNs, autoimmune disorders or autoimmune phenomena may be associated with MPNs, and genetic constitutional variants that predispose to autoimmune disorders or inflammatory phenomena also predispose to MPNs raises a hypothesis that there might be an autoimmune/inflammatory basis underlying the pathogenesis of MPNs. Recent studies have documented that MPNs are characterized by an abnormal activity of key cells of the immune system, for example, increase in monocyte/macrophage compartment, altered regulatory T cell frequency, expansion of myeloid-derived suppressor cells, and CD4/natural killer cell dysfunction. This review is focused on summarizing recent advances in our understanding of immunological defects in MPNs with accompanying translational implications.
Literatur
1.
Zurück zum Zitat Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
2.
Zurück zum Zitat Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.PubMedCentralPubMedCrossRef Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One. 2013;8(3):e57911.PubMedCentralPubMedCrossRef Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One. 2013;8(3):e57911.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Hasselblach H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990;34(4):291–300.CrossRef Hasselblach H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990;34(4):291–300.CrossRef
5.
Zurück zum Zitat Vainchenker W, Constantinescu SN. JAK/STAT signaling in haematological malignancies. Oncogene. 2013;32(21):2601–13.PubMedCrossRef Vainchenker W, Constantinescu SN. JAK/STAT signaling in haematological malignancies. Oncogene. 2013;32(21):2601–13.PubMedCrossRef
6.
Zurück zum Zitat Squires M, Harrison CN, Barosi G, et al. The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT). Blood. 2013; 122(2), Abstract 2070 Squires M, Harrison CN, Barosi G, et al. The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT). Blood. 2013; 122(2), Abstract 2070
7.•
Zurück zum Zitat Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53. This is an updated analysis of the results obtained with ruxolitinib in myelofibrosis patients after a 3-year follow-up. The results indicate that the drug, an anti-cytokine agent, is able to prolong the survival of patients.PubMedCrossRef Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–53. This is an updated analysis of the results obtained with ruxolitinib in myelofibrosis patients after a 3-year follow-up. The results indicate that the drug, an anti-cytokine agent, is able to prolong the survival of patients.PubMedCrossRef
8.
Zurück zum Zitat Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822–8.PubMedCentralPubMedCrossRef Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822–8.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216–20.PubMedCentralPubMedCrossRef Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216–20.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Hemminki K, Liu X, Försti A, Ji J, Sundquist J, Sundquist K. Subsequent leukaemia in autoimmune disease patients. Br J Haematol. 2013;161(5):677–87.PubMedCrossRef Hemminki K, Liu X, Försti A, Ji J, Sundquist J, Sundquist K. Subsequent leukaemia in autoimmune disease patients. Br J Haematol. 2013;161(5):677–87.PubMedCrossRef
11.
Zurück zum Zitat Guillot X, Moldovan M, Vidon C, Wendling D. Myelofibrosis-related arthritis successfully treated with hydroxyurea. Case Rep Rheumatol. 2014;2014:869743.PubMedCentralPubMed Guillot X, Moldovan M, Vidon C, Wendling D. Myelofibrosis-related arthritis successfully treated with hydroxyurea. Case Rep Rheumatol. 2014;2014:869743.PubMedCentralPubMed
12.
Zurück zum Zitat Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC. Myeloproliferative neoplasms in five multiple sclerosis patients. Leuk Res Rep. 2013;2(2):61–3.PubMedCentralPubMed Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC. Myeloproliferative neoplasms in five multiple sclerosis patients. Leuk Res Rep. 2013;2(2):61–3.PubMedCentralPubMed
13.
Zurück zum Zitat Ayvaz OC, Yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012;32(1):269–71.PubMedCrossRef Ayvaz OC, Yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012;32(1):269–71.PubMedCrossRef
14.
Zurück zum Zitat Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: report of two cases and review of the literature. Inflamm Bowel Dis. 2011;17(2):674–5.PubMedCrossRef Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: report of two cases and review of the literature. Inflamm Bowel Dis. 2011;17(2):674–5.PubMedCrossRef
15.
Zurück zum Zitat Ong A, Quach H, Leech M. Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis. J Clin Rheumatol. 2011;17(4):211–3.PubMedCrossRef Ong A, Quach H, Leech M. Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis. J Clin Rheumatol. 2011;17(4):211–3.PubMedCrossRef
16.
Zurück zum Zitat Muslimani A, Ahluwalia MS, Palaparty P, Daw HA. Idiopathic myelofibrosis associated with dermatomyositis. Am J Hematol. 2006;81(7):559–60.PubMedCrossRef Muslimani A, Ahluwalia MS, Palaparty P, Daw HA. Idiopathic myelofibrosis associated with dermatomyositis. Am J Hematol. 2006;81(7):559–60.PubMedCrossRef
17.
Zurück zum Zitat Ito A, Umeda M, Koike T, Naruse S, Fujita N. A case of dermatomyositis associated with chronic idiopathic myelofibrosis. Rinsho Shinkeigaku. 2006;46(3):210–3.PubMed Ito A, Umeda M, Koike T, Naruse S, Fujita N. A case of dermatomyositis associated with chronic idiopathic myelofibrosis. Rinsho Shinkeigaku. 2006;46(3):210–3.PubMed
18.
Zurück zum Zitat Jain V, Maheshwari A, Gulati S, Kabra M, Kalra V. Juvenile rheumatoid arthritis with myelofibrosis with myeloid metaplasia. Indian J Pediatr. 2005;72(9):789–91.PubMedCrossRef Jain V, Maheshwari A, Gulati S, Kabra M, Kalra V. Juvenile rheumatoid arthritis with myelofibrosis with myeloid metaplasia. Indian J Pediatr. 2005;72(9):789–91.PubMedCrossRef
19.
Zurück zum Zitat Camós M, Arellano-Rodrigo E, Abelló D, et al. Idiopathic myelofibrosis associated with classic polyarteritis nodosa. Leuk Lymphoma. 2003;44(3):539–41.PubMedCrossRef Camós M, Arellano-Rodrigo E, Abelló D, et al. Idiopathic myelofibrosis associated with classic polyarteritis nodosa. Leuk Lymphoma. 2003;44(3):539–41.PubMedCrossRef
20.
Zurück zum Zitat Arellano-Rodrigo E, Esteve J, Giné E, Panés J, Cervantes F. Idiopathic myelofibrosis associated with ulcerative colitis. Leuk Lymphoma. 2002;43(7):1481–3.PubMedCrossRef Arellano-Rodrigo E, Esteve J, Giné E, Panés J, Cervantes F. Idiopathic myelofibrosis associated with ulcerative colitis. Leuk Lymphoma. 2002;43(7):1481–3.PubMedCrossRef
21.
Zurück zum Zitat Hernández-Boluda JC, Jiménez M, Rosiñol L, Cervantes F. Idiopathic myelofibrosis associated with primary biliary cirrhosis. Leuk Lymphoma. 2002;43(3):673–4.PubMedCrossRef Hernández-Boluda JC, Jiménez M, Rosiñol L, Cervantes F. Idiopathic myelofibrosis associated with primary biliary cirrhosis. Leuk Lymphoma. 2002;43(3):673–4.PubMedCrossRef
22.
Zurück zum Zitat Tsiara SN, Christou L, Panteli K, Anastasopoulos D, Bourantas KL. A patient with essential thrombocytosis and multiple sclerosis. Eur J Intern Med. 2000;11(6):345–7.PubMedCrossRef Tsiara SN, Christou L, Panteli K, Anastasopoulos D, Bourantas KL. A patient with essential thrombocytosis and multiple sclerosis. Eur J Intern Med. 2000;11(6):345–7.PubMedCrossRef
23.
Zurück zum Zitat Ros Expósito S, Rodríguez Moreno J, Campoy Reolid E, Roig Escofet D. Idiopathic myelofibrosis associated with rheumatoid arthritis. Med Clin (Barc). 1994;102(7):277. Ros Expósito S, Rodríguez Moreno J, Campoy Reolid E, Roig Escofet D. Idiopathic myelofibrosis associated with rheumatoid arthritis. Med Clin (Barc). 1994;102(7):277.
24.
Zurück zum Zitat Rondeau E, Solal-Celigny P, Dhermy D, et al. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol. 1983;53(3):467–75.PubMedCrossRef Rondeau E, Solal-Celigny P, Dhermy D, et al. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol. 1983;53(3):467–75.PubMedCrossRef
25.
Zurück zum Zitat Lang JM, Oberling F, Giron C, Mayer S. Autoimmunité et deficit de immunité cellulaire au cours des fibroses primitives de la moelle osseuse. Ann Immunol Paris. 1977;128(1–2):291–3.PubMed Lang JM, Oberling F, Giron C, Mayer S. Autoimmunité et deficit de immunité cellulaire au cours des fibroses primitives de la moelle osseuse. Ann Immunol Paris. 1977;128(1–2):291–3.PubMed
26.
Zurück zum Zitat Caligaris Cappio F, Vigliani R, Novarino A, et al. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol. 1981;49(1):17–21.CrossRef Caligaris Cappio F, Vigliani R, Novarino A, et al. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol. 1981;49(1):17–21.CrossRef
27.
Zurück zum Zitat Khumbanonda M, Horowitz HI, Eysker ME. Coomb’s positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci. 1969;258(2):89–93.PubMedCrossRef Khumbanonda M, Horowitz HI, Eysker ME. Coomb’s positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci. 1969;258(2):89–93.PubMedCrossRef
28.••
Zurück zum Zitat Barcellini W, Iurlo A, Radice T, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013;37(11):1509–15. The paper reports the results of autoimmune tests in 100 patients with MF, and document that 45% of the patients had positive anti-erythrocyte antibodies by mitogen-stimulated direct antiglobulin test, a functional assay able to disclose a latent autoimmunity.PubMedCrossRef Barcellini W, Iurlo A, Radice T, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013;37(11):1509–15. The paper reports the results of autoimmune tests in 100 patients with MF, and document that 45% of the patients had positive anti-erythrocyte antibodies by mitogen-stimulated direct antiglobulin test, a functional assay able to disclose a latent autoimmunity.PubMedCrossRef
29.
Zurück zum Zitat Bernhardt B, Valletta M. Lupus anticoagulant in myelofibrosis. Am J Med Sci. 1976;272(2):229–31.PubMedCrossRef Bernhardt B, Valletta M. Lupus anticoagulant in myelofibrosis. Am J Med Sci. 1976;272(2):229–31.PubMedCrossRef
30.
Zurück zum Zitat Hasselbalch H, Berild D, Paaske-Hansen O. Platelet-associated IgG and IgM in myelofibrosis. Scand J Haematol. 1984;32(5):488–92.PubMedCrossRef Hasselbalch H, Berild D, Paaske-Hansen O. Platelet-associated IgG and IgM in myelofibrosis. Scand J Haematol. 1984;32(5):488–92.PubMedCrossRef
31.
Zurück zum Zitat Gordon BR, Coleman M, Kohen P, Day NK. Immunological abnormalities in myelofibrosis with activation of the complement system. Blood. 1981;58(5):904–10.PubMed Gordon BR, Coleman M, Kohen P, Day NK. Immunological abnormalities in myelofibrosis with activation of the complement system. Blood. 1981;58(5):904–10.PubMed
32.
Zurück zum Zitat Lewis CM, Pegrum GD. Immune complexes in myelofibrosis: a possible guide to management. Br J Haematol. 1978;39(2):233–9.PubMedCrossRef Lewis CM, Pegrum GD. Immune complexes in myelofibrosis: a possible guide to management. Br J Haematol. 1978;39(2):233–9.PubMedCrossRef
33.
Zurück zum Zitat Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Med (Baltimore). 1994;73(3):145–52.CrossRef Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Med (Baltimore). 1994;73(3):145–52.CrossRef
34.
Zurück zum Zitat Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72(1):8–12.PubMedCrossRef Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72(1):8–12.PubMedCrossRef
35.
Zurück zum Zitat Pillai A, Gautam M, Williamson H, Martlew V, Nash J, Thachil J. Multisystem failure due to three coexisting autoimmune diseases. Intern Med. 2009;48(10):837–42.PubMedCrossRef Pillai A, Gautam M, Williamson H, Martlew V, Nash J, Thachil J. Multisystem failure due to three coexisting autoimmune diseases. Intern Med. 2009;48(10):837–42.PubMedCrossRef
36.
Zurück zum Zitat Bass RD, Pullarkat V, Feinstein DI, Kaul A, Winberg CD, Brynes RK. Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. Am J Clin Pathol. 2001;116(2):211–6.PubMedCrossRef Bass RD, Pullarkat V, Feinstein DI, Kaul A, Winberg CD, Brynes RK. Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. Am J Clin Pathol. 2001;116(2):211–6.PubMedCrossRef
37.
Zurück zum Zitat Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol. 2013;91(4):378–9.PubMed Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol. 2013;91(4):378–9.PubMed
38.
Zurück zum Zitat Sacré K, Aguilar C, Deligny C, et al. Lytic bone lesions in lupus-associated myelofibrosis. Lupus. 2010;19(3):313–6.PubMedCrossRef Sacré K, Aguilar C, Deligny C, et al. Lytic bone lesions in lupus-associated myelofibrosis. Lupus. 2010;19(3):313–6.PubMedCrossRef
39.
Zurück zum Zitat Pereira RM, Velloso ER, Menezes Y, Gualandro S, Vassalo J, Yoshinari NH. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol. 1998;17(3):219–22.PubMedCrossRef Pereira RM, Velloso ER, Menezes Y, Gualandro S, Vassalo J, Yoshinari NH. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol. 1998;17(3):219–22.PubMedCrossRef
40.
Zurück zum Zitat Wanitpongpun C, Teawtrakul N, Mahakkanukrauh A, Siritunyaporn S, Sirijerachai C, Chansung K. Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia. Clin Exp Rheumatol. 2012;30(6):825–9.PubMed Wanitpongpun C, Teawtrakul N, Mahakkanukrauh A, Siritunyaporn S, Sirijerachai C, Chansung K. Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia. Clin Exp Rheumatol. 2012;30(6):825–9.PubMed
41.
Zurück zum Zitat Takahashi T. Autoimmune myelofibrosis accompanied by Sjögren’s syndrome in a 47, XXX/46, XX mosaic woman. Intern Med. 2014;53(7):783–7.PubMedCrossRef Takahashi T. Autoimmune myelofibrosis accompanied by Sjögren’s syndrome in a 47, XXX/46, XX mosaic woman. Intern Med. 2014;53(7):783–7.PubMedCrossRef
42.
Zurück zum Zitat Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.PubMedCentralPubMedCrossRef Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.PubMedCrossRef Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.PubMedCrossRef
44.
Zurück zum Zitat Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517–23.PubMedCentralPubMedCrossRef Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517–23.PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.PubMedCentralPubMedCrossRef Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res. 2010;690(1–2):108–15.PubMedCrossRef Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res. 2010;690(1–2):108–15.PubMedCrossRef
47.
Zurück zum Zitat Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–9.PubMedCentralPubMedCrossRef Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–9.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Varricchio L, Godbold J, Scott SA, et al. Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood. 2011;118(2):473–4.PubMedCentralPubMedCrossRef Varricchio L, Godbold J, Scott SA, et al. Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood. 2011;118(2):473–4.PubMedCentralPubMedCrossRef
49.••
Zurück zum Zitat Poletto V, Rosti V, Villani L, et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood. 2012;120(15):3112–7. The paper documents that the polymorphism A3669G of the glucocorticoid receptor is a susceptibility factor for myelofibrosis. Since the polymorphism is also a predisposing factor for rheumatoid arthritis, it represents a proof of concept of common genetic predisposition to MPNs and inflammatory disorders.PubMedCentralPubMedCrossRef Poletto V, Rosti V, Villani L, et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood. 2012;120(15):3112–7. The paper documents that the polymorphism A3669G of the glucocorticoid receptor is a susceptibility factor for myelofibrosis. Since the polymorphism is also a predisposing factor for rheumatoid arthritis, it represents a proof of concept of common genetic predisposition to MPNs and inflammatory disorders.PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Derijk RH, Schaaf MJ, Turner G, et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol. 2001;28(11):2383–8.PubMed Derijk RH, Schaaf MJ, Turner G, et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol. 2001;28(11):2383–8.PubMed
51.
Zurück zum Zitat Varricchio L, Masselli E, Alfani E, et al. The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood. 2011;118(2):425–36.PubMedCentralPubMedCrossRef Varricchio L, Masselli E, Alfani E, et al. The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood. 2011;118(2):425–36.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat van Oosten MJ, Dolhain RJ, Koper JW, et al. Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R159.PubMedCentralPubMedCrossRef van Oosten MJ, Dolhain RJ, Koper JW, et al. Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R159.PubMedCentralPubMedCrossRef
53.
Zurück zum Zitat Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371–4.PubMedCentralPubMedCrossRef Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371–4.PubMedCentralPubMedCrossRef
54.
Zurück zum Zitat Wang F, Fu P, Pang Y, et al. TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma. Tumour Biol. 2014;35(5):4667–72.PubMedCrossRef Wang F, Fu P, Pang Y, et al. TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma. Tumour Biol. 2014;35(5):4667–72.PubMedCrossRef
55.
Zurück zum Zitat Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012;36(11):1387–92.PubMedCrossRef Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012;36(11):1387–92.PubMedCrossRef
56.
Zurück zum Zitat Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma. 2013;54(10):2269–73.PubMedCrossRef Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma. 2013;54(10):2269–73.PubMedCrossRef
57.
Zurück zum Zitat Skov V, Larsen TS, Thomassen M, et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87(1):54–60.PubMedCrossRef Skov V, Larsen TS, Thomassen M, et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87(1):54–60.PubMedCrossRef
58.
Zurück zum Zitat Kremer M, Horn T, Koch I, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol. 2008;32(6):928–35.PubMedCrossRef Kremer M, Horn T, Koch I, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol. 2008;32(6):928–35.PubMedCrossRef
59.
Zurück zum Zitat Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007;25(9):2358–62.PubMedCrossRef Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007;25(9):2358–62.PubMedCrossRef
60.
Zurück zum Zitat Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007;21(10):2206–7.PubMedCrossRef Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007;21(10):2206–7.PubMedCrossRef
61.
Zurück zum Zitat Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136(5):745–51.PubMedCrossRef Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136(5):745–51.PubMedCrossRef
62.
Zurück zum Zitat Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica. 2007;92(2):258–9.PubMedCrossRef Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica. 2007;92(2):258–9.PubMedCrossRef
63.
Zurück zum Zitat Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101(5):1981–3.PubMedCrossRef Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101(5):1981–3.PubMedCrossRef
64.
Zurück zum Zitat Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71–7.PubMedCrossRef Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71–7.PubMedCrossRef
65.
Zurück zum Zitat Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65(2):104–8.PubMedCrossRef Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000;65(2):104–8.PubMedCrossRef
66.
Zurück zum Zitat Ginsberg HN, Le NA, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35(9):878–82.PubMedCrossRef Ginsberg HN, Le NA, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35(9):878–82.PubMedCrossRef
67.
Zurück zum Zitat Ginsberg H, Gilbert HS. Hypocholesterolemia in myeloproliferative diseases with myelofibrosis. Prog Clin Biol Res. 1984;154:345–57.PubMed Ginsberg H, Gilbert HS. Hypocholesterolemia in myeloproliferative diseases with myelofibrosis. Prog Clin Biol Res. 1984;154:345–57.PubMed
68.
Zurück zum Zitat Ginsberg H, Gilbert HS, Gibson JC, Le NA, Brown WV. Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med. 1982;96(3):311–6.PubMedCrossRef Ginsberg H, Gilbert HS, Gibson JC, Le NA, Brown WV. Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med. 1982;96(3):311–6.PubMedCrossRef
69.
Zurück zum Zitat Thiele J, Kvasnicka HM, Boeltken B. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies. Leuk Res. 1999;23(11):983–5.PubMedCrossRef Thiele J, Kvasnicka HM, Boeltken B. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies. Leuk Res. 1999;23(11):983–5.PubMedCrossRef
70.
Zurück zum Zitat Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.PubMedCrossRef Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–9.PubMedCrossRef
71.
Zurück zum Zitat Boiocchi L, Espinal-Witter R, Geyer JT, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26(2):204–12.PubMedCrossRef Boiocchi L, Espinal-Witter R, Geyer JT, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26(2):204–12.PubMedCrossRef
72.
Zurück zum Zitat Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.PubMedCrossRef Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.PubMedCrossRef
73.
Zurück zum Zitat Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165(4):2271–7.PubMedCrossRef Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165(4):2271–7.PubMedCrossRef
74.
Zurück zum Zitat Chang VT, Yook C, Rameshwar P. Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis. Leuk Lymphoma. 2013;54(3):631–8.PubMedCrossRef Chang VT, Yook C, Rameshwar P. Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis. Leuk Lymphoma. 2013;54(3):631–8.PubMedCrossRef
75.
Zurück zum Zitat Kundra A, Baptiste S, Chen C, Sindhu H, Wang JJC. Programmed cell death receptor (PD-1), PD-1 ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis. Blood. 2013;122(21) Abstract n. 2837 Kundra A, Baptiste S, Chen C, Sindhu H, Wang JJC. Programmed cell death receptor (PD-1), PD-1 ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis. Blood. 2013;122(21) Abstract n. 2837
76.
Zurück zum Zitat Zhao WB, Li Y, Liu X, Zhang LY, Wang X. Involvement of CD4+CD25+ regulatory T cells in the pathogenesis of polycythaemia vera. Chin Med J (Engl). 2008;121(18):1781–6. Zhao WB, Li Y, Liu X, Zhang LY, Wang X. Involvement of CD4+CD25+ regulatory T cells in the pathogenesis of polycythaemia vera. Chin Med J (Engl). 2008;121(18):1781–6.
77.
Zurück zum Zitat Keohane C, Kordasti SY, Seidl T et al. JAK inhibition reduces CD25 high CD27+FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013;122(21) Abstract n 4092 Keohane C, Kordasti SY, Seidl T et al. JAK inhibition reduces CD25 high CD27+FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013;122(21) Abstract n 4092
78.
Zurück zum Zitat Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011;118(8):2170–3.PubMedCrossRef Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011;118(8):2170–3.PubMedCrossRef
79.
Zurück zum Zitat Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.PubMedCrossRef Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.PubMedCrossRef
80.
Zurück zum Zitat Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.PubMedCrossRef Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.PubMedCrossRef
81.
Zurück zum Zitat Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2005;105(2):464–73.PubMedCrossRef Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2005;105(2):464–73.PubMedCrossRef
82.
Zurück zum Zitat Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002;20(4):178–83.PubMedCrossRef Hermouet S, Godard A, Pineau D, et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002;20(4):178–83.PubMedCrossRef
83.
Zurück zum Zitat Desterke C, Bilhou-Nabéra C, Guerton B, et al. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011;71(8):2901–15.PubMedCrossRef Desterke C, Bilhou-Nabéra C, Guerton B, et al. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011;71(8):2901–15.PubMedCrossRef
84.
Zurück zum Zitat Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica. 2013;98(7):1073–80.PubMedCentralPubMedCrossRef Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A, Pahl HL. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica. 2013;98(7):1073–80.PubMedCentralPubMedCrossRef
85.
Zurück zum Zitat Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88(12):4534–46.PubMed Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88(12):4534–46.PubMed
86.
Zurück zum Zitat Campanelli R, Rosti V, Villani L, et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine. 2011;53(1):100–6.PubMedCrossRef Campanelli R, Rosti V, Villani L, et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine. 2011;53(1):100–6.PubMedCrossRef
87.
Zurück zum Zitat Le Bousse-Kerdiles MC, Martyre MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw. 2008;19(2):69–80.PubMed Le Bousse-Kerdiles MC, Martyre MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw. 2008;19(2):69–80.PubMed
88.
Zurück zum Zitat Vannucchi AM, Bianchi L, Paoletti F, et al. A pathologic pathway linking thrombopoietin, GATA-1 and TGF-β1 in the development of myelofibrosis. Blood. 2005;105(9):3493–501.PubMedCrossRef Vannucchi AM, Bianchi L, Paoletti F, et al. A pathologic pathway linking thrombopoietin, GATA-1 and TGF-β1 in the development of myelofibrosis. Blood. 2005;105(9):3493–501.PubMedCrossRef
89.
Zurück zum Zitat Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol. 2006;34(12):1617–23.PubMedCrossRef Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol. 2006;34(12):1617–23.PubMedCrossRef
90.
Zurück zum Zitat Badalucco S, Di Buduo CA, Campanelli R, et al. Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica. 2013;98(4):514–7.PubMedCentralPubMedCrossRef Badalucco S, Di Buduo CA, Campanelli R, et al. Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica. 2013;98(4):514–7.PubMedCentralPubMedCrossRef
91.
Zurück zum Zitat Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2084–6.PubMedCrossRef Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2084–6.PubMedCrossRef
92.
Zurück zum Zitat Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–8.PubMedCentralPubMedCrossRef Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–8.PubMedCentralPubMedCrossRef
93.
Zurück zum Zitat Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.PubMedCrossRef Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.PubMedCrossRef
94.
Zurück zum Zitat Centenara E, Guarnone R, Ippoliti G, Barosi G. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica. 1998;83(7):622–6.PubMed Centenara E, Guarnone R, Ippoliti G, Barosi G. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica. 1998;83(7):622–6.PubMed
95.
Zurück zum Zitat Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother. 2011;12(10):1597–611.PubMedCrossRef Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother. 2011;12(10):1597–611.PubMedCrossRef
96.
Zurück zum Zitat Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735.PubMedCentralPubMedCrossRef Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735.PubMedCentralPubMedCrossRef
97.•
Zurück zum Zitat Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;10. The paper provides evidence that JAK1/JAK2 inhibitor ruxolitinib improves pulmonary hypertension associated with MF and reduces the level of inflammatory cytokines. This may be taken as evidence that pulmonary hypertension in MF has an inflammatory pathogenesis. Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;10. The paper provides evidence that JAK1/JAK2 inhibitor ruxolitinib improves pulmonary hypertension associated with MF and reduces the level of inflammatory cytokines. This may be taken as evidence that pulmonary hypertension in MF has an inflammatory pathogenesis.
98.
Zurück zum Zitat Avanzini MA, Bernardo ME, Novara F, et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia. 2014. Avanzini MA, Bernardo ME, Novara F, et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia. 2014.
99.
Zurück zum Zitat Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49–58.PubMedCrossRef Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49–58.PubMedCrossRef
100.
Zurück zum Zitat Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217–25.PubMedCrossRef Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217–25.PubMedCrossRef
101.
Zurück zum Zitat Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-β therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55(2):450–2.PubMedCrossRef Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-β therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55(2):450–2.PubMedCrossRef
Metadaten
Titel
An Immune Dysregulation in MPN
verfasst von
Giovanni Barosi
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2014
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-014-0227-0

Neu im Fachgebiet Onkologie

KI erlaubt neue Einsichten in die Krebsprognose

Forschende sind in komplexen Real-World-Daten des Westdeutschen Tumorzentrums auf bisher weniger beachtete Zusammenhänge von bestimmten Risikomarkern mit der Prognose gestoßen. Möglich gemacht hat’s ein Verfahren namens „erklärbare KI“, mit dem sich hunderte Tumor- und Patientenmerkmale gleichzeitig betrachten lassen.

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.